Expert opinion on therapeutic targets

Keyphrases

Publications

volume 28, number 4, 2024

Shiyu Xiao, Hongxia Chen, Yunpeng Bai, Zhong-Yin Zhang, Yan Liu
Targeting PRL phosphatases in hematological malignancies. Expert opinion on therapeutic targets 28 (4) (2024)
Ozasvi R Shanker, Sonali Kumar, Jyotirmoy Banerjee, Manjari Tripathi, P Sarat Chandra, Aparna Banerjee Dixit
Role of non-receptor tyrosine kinases in epilepsy: significance and potential as therapeutic targets. Expert opinion on therapeutic targets 28 (4) (2024)
Hui Chen, Xiangna Guan, Chi He, Tingting Lu, Xingyu Lin, Xuebin Liao
Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress. Expert opinion on therapeutic targets 28 (4) (2024)
Shiqi Fu, Xiuzu Song
The clinical and immunological features of alopecia areata following SARS-CoV-2 infection or COVID-19 vaccines. Expert opinion on therapeutic targets 28 (4) (2024)
Hui Chen, Xiangna Guan, Chi He, Tingting Lu, Xingyu Lin, Xuebin Liao
Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress. Expert opinion on therapeutic targets 28 (4) (2024)
Shiyu Xiao, Hongxia Chen, Yunpeng Bai, Zhong-Yin Zhang, Yan Liu
Targeting PRL phosphatases in hematological malignancies. Expert opinion on therapeutic targets 28 (4) (2024)
Dorothea Noll, Dorothea Kehr, Patrick Most, Julia Ritterhoff
S100A1: a promising therapeutic target for heart failure. Expert opinion on therapeutic targets 28 (4) (2024)

volume 28, number 5, 2024

Hsin-Yu Ho, Mu-Kuan Chen, Chia-Chieh Lin, Yu-Sheng Lo, Yi-Ching Chuang, Ming-Ju Hsieh
Arenobufagin induces cell apoptosis by modulating the cell cycle regulator claspin and the JNK pathway in nasopharyngeal carcinoma cells. Expert opinion on therapeutic targets 28 (5) (2024)
Tingting Li, Qussay Marashly, Jitae A Kim, Na Li, Mihail G Chelu
Cardiac conduction diseases: understanding the molecular mechanisms to uncover targets for future treatments. Expert opinion on therapeutic targets 28 (5) (2024)
Chandra K Singh, Sofia Fernandez, Gagan Chhabra, Gabriella R Zaemisch, Ayaan Nihal, Jenna Swanlund, Naveed Ansari, Zan Said, Hao Chang, Nihal Ahmad
The role of collagen triple helix repeat containing 1 (CTHRC1) in cancer development and progression. Expert opinion on therapeutic targets 28 (5) (2024)
Camilla Muccini, Antonella Castagna
HIV Pol: does it offer therapeutic targets for HIV? Expert opinion on therapeutic targets 28 (5) (2024)
Harry Ridgway, Graham J Moore, Laura Kate Gadanec, Anthony Zulli, Vasso Apostolopoulos, Weronika Hoffmann, Katarzyna Węgrzyn, Niki Vassilaki, George Mpekoulis, Marios Zouridakis, Petros Giastas, Veroniki P Vidali, Konstantinos Kelaidonis, Minos-Timotheos Matsoukas, Marios Dimitriou, Thomas Mauromoustakos, Sotirios Tsiodras, Vassilis G Gorgoulis, Ioannis Karakasiliotis, Christos T Chasapis, John M Matsoukas
Novel benzimidazole angiotensin receptor blockers with anti-SARS-CoV-2 activity equipotent to that of nirmatrelvir: computational and enzymatic studies. Expert opinion on therapeutic targets 28 (5) (2024)
Rafael Elias Marques, Jacqueline Farinha Shimizu, Maurício Lacerda Nogueira, Nikos Vasilakis
Current challenges in the discovery of treatments against Mayaro fever. Expert opinion on therapeutic targets 28 (5) (2024)
Hsin-Yu Ho, Mu-Kuan Chen, Chia-Chieh Lin, Yu-Sheng Lo, Yi-Ching Chuang, Ming-Ju Hsieh
Arenobufagin induces cell apoptosis by modulating the cell cycle regulator claspin and the JNK pathway in nasopharyngeal carcinoma cells. Expert opinion on therapeutic targets 28 (5) (2024)
Vlad Dumitru Brata, Frank Tacke
Fatty liver disease: time to target CCR5? Expert opinion on therapeutic targets 28 (5) (2024)
Rafael Elias Marques, Jacqueline Farinha Shimizu, Maurício Lacerda Nogueira, Nikos Vasilakis
Current challenges in the discovery of treatments against Mayaro fever. Expert opinion on therapeutic targets 28 (5) (2024)
Stephen J Nicholls, Adam J Nelson
New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand? Expert opinion on therapeutic targets 28 (5) (2024)
Saba Ubaid, Mohammad Kashif, Yusra Laiq, Akshay Kumar Nayak, Vipin Kumar, Vivek Singh
Targeting HIF-1α in sickle cell disease and cancer: unraveling therapeutic opportunities and risks. Expert opinion on therapeutic targets 28 (5) (2024)
Aline Silva de Miranda, Eliana Cristina de Brito Toscano, Jason C O'Connor, Antonio Lucio Teixeira
Targeting inflammasome complexes as a novel therapeutic strategy for mood disorders. Expert opinion on therapeutic targets 28 (5) (2024)
Chandra K Singh, Sofia Fernandez, Gagan Chhabra, Gabriella R Zaemisch, Ayaan Nihal, Jenna Swanlund, Naveed Ansari, Zan Said, Hao Chang, Nihal Ahmad
The role of collagen triple helix repeat containing 1 (CTHRC1) in cancer development and progression. Expert opinion on therapeutic targets 28 (5) (2024)
Rafael Elias Marques, Jacqueline Farinha Shimizu, Maurício Lacerda Nogueira, Nikos Vasilakis
Current challenges in the discovery of treatments against Mayaro fever. Expert opinion on therapeutic targets 28 (5) (2024)
Harry Ridgway, Graham J Moore, Laura Kate Gadanec, Anthony Zulli, Vasso Apostolopoulos, Weronika Hoffmann, Katarzyna Węgrzyn, Niki Vassilaki, George Mpekoulis, Marios Zouridakis, Petros Giastas, Veroniki P Vidali, Konstantinos Kelaidonis, Minos-Timotheos Matsoukas, Marios Dimitriou, Thomas Mauromoustakos, Sotirios Tsiodras, Vassilis G Gorgoulis, Ioannis Karakasiliotis, Christos T Chasapis, John M Matsoukas
Novel benzimidazole angiotensin receptor blockers with anti-SARS-CoV-2 activity equipotent to that of nirmatrelvir: computational and enzymatic studies. Expert opinion on therapeutic targets 28 (5) (2024)
Tingting Li, Qussay Marashly, Jitae A Kim, Na Li, Mihail G Chelu
Cardiac conduction diseases: understanding the molecular mechanisms to uncover targets for future treatments. Expert opinion on therapeutic targets 28 (5) (2024)
Chandra K Singh, Sofia Fernandez, Gagan Chhabra, Gabriella R Zaemisch, Ayaan Nihal, Jenna Swanlund, Naveed Ansari, Zan Said, Hao Chang, Nihal Ahmad
The role of collagen triple helix repeat containing 1 (CTHRC1) in cancer development and progression. Expert opinion on therapeutic targets 28 (5) (2024)
Vlad Dumitru Brata, Frank Tacke
Fatty liver disease: time to target CCR5? Expert opinion on therapeutic targets 28 (5) (2024)

volume 28, number 6, 2024

Ryan Gilroy, Gordan Lauc
Glycoproteins and longevity: an interview with Professor Gordan Lauc. Expert opinion on therapeutic targets 28 (6) (2024)
Caitlin J Lewis, Aubrey D N J de Grey
Combining rejuvenation interventions in rodents: a milestone in biomedical gerontology whose time has come. Expert opinion on therapeutic targets 28 (6) (2024)
Maria Vedunova, Olga Borysova, Grigory Kozlov, Anna-Maria Zharova, Ivan Morgunov, Aleksey Igorevich Moskalev
Candidate molecular targets uncovered in mouse lifespan extension studies. Expert opinion on therapeutic targets 28 (6) (2024)

volume 28, number 7, 2024

Zhao-Xing Gao, Tian He, Peng Zhang, Xiao Hu, Man Ge, Yi-Qing Xu, Peng Wang, Hai-Feng Pan
Epigenetic regulation of immune cells in systemic lupus erythematosus: insight from chromatin accessibility. Expert opinion on therapeutic targets 28 (7) (2024)
Kajetan Kiełbowski, Estera Bakinowska, Aleksandra Wiktoria Bratborska, Andrzej Pawlik
The role of adipokines in the pathogenesis of psoriasis - a focus on resistin, omentin-1 and vaspin. Expert opinion on therapeutic targets 28 (7) (2024)
Dalton W Staller, Robert G Bennett, Ram I Mahato
Therapeutic perspectives on PDE4B inhibition in adipose tissue dysfunction and chronic liver injury. Expert opinion on therapeutic targets 28 (7) (2024)
Evgeny N Imyanitov, Natalia V Mitiushkina, Ekatherina Sh Kuligina, Vladislav I Tiurin, Aigul R Venina
Pathways and targeting avenues of BRAF in non-small cell lung cancer. Expert opinion on therapeutic targets 28 (7) (2024)
Serena Bellani, Philip L Molyneaux, Toby M Maher, Paolo Spagnolo
Potential of αvβ6 and αvβ1 integrin inhibition for treatment of idiopathic pulmonary fibrosis. Expert opinion on therapeutic targets 28 (7) (2024)
Dalton W Staller, Robert G Bennett, Ram I Mahato
Therapeutic perspectives on PDE4B inhibition in adipose tissue dysfunction and chronic liver injury. Expert opinion on therapeutic targets 28 (7) (2024)
Jonas Sigurd Mortensen, Amalie N L Mikkelsen, Petrine Wellendorph
Ways of modulating GABA transporters to treat neurological disease. Expert opinion on therapeutic targets 28 (7) (2024)
Mohammad Sadegh Gheibzadeh, Clemente Capasso, Claudiu T Supuran, Reza Zolfaghari Emameh
Antibacterial carbonic anhydrase inhibitors targeting Vibrio cholerae enzymes. Expert opinion on therapeutic targets 28 (7) (2024)
Nadia L van der Meijs, Maria Alejandra Travecedo, Filipa Marcelo, Sandra J van Vliet
The pleiotropic CLEC10A: implications for harnessing this receptor in the tumor microenvironment. Expert opinion on therapeutic targets 28 (7) (2024)
Serena Bellani, Philip L Molyneaux, Toby M Maher, Paolo Spagnolo
Potential of αvβ6 and αvβ1 integrin inhibition for treatment of idiopathic pulmonary fibrosis. Expert opinion on therapeutic targets 28 (7) (2024)

volume 28, number 8, 2024

Paolo Fagone, Katia Mangano, Ferdinando Nicoletti
The emerging role of Tetraspanin 32 in autoimmune diseases: from discovery to relevant theranostics? Expert opinion on therapeutic targets 28 (8) (2024)
Paolo Fagone, Katia Mangano, Ferdinando Nicoletti
The emerging role of Tetraspanin 32 in autoimmune diseases: from discovery to relevant theranostics? Expert opinion on therapeutic targets 28 (8) (2024)
Chadi G Abdallah, Amanda J F Tamman
Synaptic fidelity for drug development: is it time to move beyond glutamate release and receptors? Expert opinion on therapeutic targets 28 (8) (2024)
Paolo Maione, Valentina Palma, Giuseppina Pucillo, Cesare Gridelli
Targeting ALK receptors in non-small cell lung cancer: what is the road ahead? Expert opinion on therapeutic targets 28 (8) (2024)
Paolo Maione, Valentina Palma, Giuseppina Pucillo, Cesare Gridelli
Targeting ALK receptors in non-small cell lung cancer: what is the road ahead? Expert opinion on therapeutic targets 28 (8) (2024)
Chadi G Abdallah, Amanda J F Tamman
Synaptic fidelity for drug development: is it time to move beyond glutamate release and receptors? Expert opinion on therapeutic targets 28 (8) (2024)
Anika Wu, Daehoon Lee, Wen-Cheng Xiong
VPS35 or retromer as a potential target for neurodegenerative disorders: barriers to progress. Expert opinion on therapeutic targets 28 (8) (2024)
Yashika Tomar, Moushumi Baidya, Jay Chadokiya, Shvetank Bhatt, Gautam Singhvi
An overview of Skp2: a promising new therapeutic target of psoriasis. Expert opinion on therapeutic targets 28 (8) (2024)
Yashika Tomar, Moushumi Baidya, Jay Chadokiya, Shvetank Bhatt, Gautam Singhvi
An overview of Skp2: a promising new therapeutic target of psoriasis. Expert opinion on therapeutic targets 28 (8) (2024)
Michal Ciebiera, Magdalena Zgliczyńska, Mohamed Ali, Obianuju Sandra Madueke Laveaux, Qiwei Yang, Monika Bączkowska, Marta Wlodarczyk, Natalia Zeber-Lubecka, Elżbieta Zarychta, Ana Corachán, Samar Alkhrait, Somayeh Vafaei, Iana Malasevskaia, Tomasz Lozinski, Piotr Laudanski, Robert Z Spaczynski, Grzegorz Jakiel, Ayman Al-Hendy
Uterine fibroids: current research on novel drug targets and innovative therapeutic strategies. Expert opinion on therapeutic targets 28 (8) (2024)
Anika Wu, Daehoon Lee, Wen-Cheng Xiong
VPS35 or retromer as a potential target for neurodegenerative disorders: barriers to progress. Expert opinion on therapeutic targets 28 (8) (2024)
Chadi G Abdallah, Amanda J F Tamman
Synaptic fidelity for drug development: is it time to move beyond glutamate release and receptors? Expert opinion on therapeutic targets 28 (8) (2024)